Monday, August 20, 2012

Sunshine Biopharma (OTCBB: SBFM) Management Bets on Lead Anti-Cancer Compound Adva-27a; Taking No Compensation

New York, New York - August 20, 2012 (Investorideas.com Newswire, Biotechindustrystocks.com) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks releases an investor alert on Sunshine Biopharma Inc. (OTCBB: SBFM) reporting on management's unusual commitment to the shareholders; no compensation is currently paid out to the top executives according to Company filings.

Key management including Chairman and CEO, Dr. Steve N. Slilaty Ph.D, Mr. Camille Sebaaly, CFO and Mr. Michele Di Turi, COO do own equity in the company.
Sunshine Biopharma's lead compound, Adva-27a is an effective and highly specific Topoisomerase II (Top2) Inhibitor that has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).
The Company recently reported that it has submitted a manuscript detailing Adva-27a preclinical research results for publication in a peer-reviewed scientific journal. Adva-27a is Sunshine Biopharma's lead anti-cancer compound which has been shown to be effective at killing multidrug resistant cancer cells in vitro. Multidrug resistant cancer cells do not respond to any of the chemotherapy drugs currently in use for cancer treatment. The manuscript, which was prepared by Sunshine Biopharma scientists in collaboration with scientists from Binghamton University in New York and from Ecole Polytechnique in Montreal ( Canada), contains a substantial amount of data compiled from experiments conducted by these scientists.
Read Investorideas.com Q&A Interview with Mr. Camille Sebaaly, CFO
http://www.investorideas.com/CO/SBFM/news/2012/07021.asp
SEC filings: http://finance.yahoo.com/q/sec?s=SBFM+SEC+Filings
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

No comments: